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Background: Recurrent vesicular hand eczema frequently has a chronic course and
needs long-term treatment.
Objectives: To evaluate health-related quality of life (HRQoL), treatment satisfaction,
and adherence in patients with vesicular hand eczema.
Methods: Patients using one main treatment for at least three months were included.
Data on HRQoL (Quality of Life in Hand Eczema Questionnaire [QOLHEQ]), treat-
ment satisfaction (Treatment Satisfaction Questionnaire for Medication, version II),
and treatment adherence (4-item Morisky Medication Adherence Scale) were col-
lected. Univariate and multivariate regression analysis were used to predict variables
associated with HRQoL.
Results: HRQoL was moderately impaired, with the highest impact in the QOLHEQ
subdomain symptoms. Female sex, more severe hand eczema, and lower treatment
satisfaction were associated with more impairment in HRQoL. Patients with severe/
very severe hand eczema had significant lower “global satisfaction” scores compared
with the other severity groups. The “global satisfaction” and treatment adherence in
patients using systemic treatment were significantly higher compared with those
with only topical treatment.
Conclusions: In patients with vesicular hand eczema disease severity affects both
HRQoL and treatment satisfaction. Systemic treatment of severe hand eczema could
improve the severity and as a result also HRQoL, treatment satisfaction, and medica-
tion adherence.
K E YWORD S
health-related quality of life, patient-reported outcomes, recurrent vesicular hand eczema,
treatment adherence, treatment satisfaction
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1 | INTRODUCTION
Hand eczema can be classified into different clinical subtypes.
Recurrent vesicular hand eczema is a typical clinical subtype that is
characterized by development of small (1-2 mm) vesicles most often
interdigitally or on the palms. The patient experiences episodes of
vesicles mostly at unpredictable intervals, which can result in a
chronic course of recurrent vesicular hand eczema. In addition to a
clinical diagnosis, it is important to classify hand eczema etiologi-
cally. The cause of hand eczema is often multifactorial. It can be
classified into one or more of the following etiological diagnoses:
allergic contact dermatitis, irritant contact dermatitis (ICD), protein
contact dermatitis, and atopic hand eczema.1
The treatment of chronic hand eczema is often challenging and at
times insufficient and unsatisfactory.2,3 Studies on treatment effec-
tiveness are mainly based on physician-reported outcomes. Fewer
studies have actually evaluated treatment benefit in terms of patient-
reported outcomes.4,5 However, chronic hand eczema can have a
remarkable impact on quality of life.2,6
To evaluate the impact of disease and treatment on physical, psy-
chological, and social functioning, the Quality of Life in Hand Eczema
Questionnaire (QOLHEQ) was recently developed. It measures overall
health-related quality of life (HRQoL) impairment in four domains:
“symptoms,” “emotions,” “functioning,” and “treatment and preven-
tion.”7,8 Other patient-reported outcomes are treatment satisfaction
and treatment adherence.9,10 Previous studies in several therapeutic
areas demonstrated a positive association between treatment satis-
faction and adherence to therapy.11 In this study we aimed to exam-
ine HRQoL, treatment satisfaction, and treatment adherence in
patients with recurrent vesicular hand eczema.
2 | METHODS
2.1 | Study design and participants
This cross-sectional study was conducted at the Dermatology Depart-
ment of the University Medical Center Groningen (Groningen, The
Netherlands), a tertiary referral center for hand eczema, between
December 2016 and May 2019. Patients were recruited while they
were on a routine visit at the outpatient clinic. Despite the fact that
some patients had mild contributing atopic dermatitis, hand eczema
was the main reason for consultation. Inclusion criteria were adult age
(>18 years old), diagnosis of chronic (>3 months) vesicular hand
eczema (classification of Menné et al1), and use of at least one main
treatment for at least three months. Patients concomitantly treated
with bursts of oral corticosteroids in the last 3 months were excluded.
Included patients needed to be able to read and understand the Dutch
language. Patients were interviewed according to a structured ques-
tionnaire. The study was reviewed and approved by the Medical Ethi-
cal Review Board of the University Medical Center Groningen
(reference METc M17.207552).
2.2 | Clinical characteristics
Data collected were basic characteristics (age, sex, education
[low/middle vs high]), employment status (low- vs high-risk occupa-
tion for hand eczema12), and elevated total and specific immunoglobu-
lin E inhalant allergens. Etiological hand eczema diagnosis was based
on fixed criteria (see Data S1).
Data on current (topical, UV, and systemic treatment) and
previous (topical, UV, systemic treatment, and hospitalization)
treatments for hand eczema were collected. All patients with
vesicular hand eczema were treated according to the Dutch
guidelines of hand eczema.13,14 Previous treatment with oral cor-
ticosteroids for over 2 weeks was counted as a history of sys-
temic treatment. The current treatment was based on the most
potent medication (systemic treatment vs nonsystemic treat-
ment). Patients with systemic treatment may have used concomi-
tantly topical corticosteroids. Disease severity was assessed by
the physician with the photographic guide of Coenraads et al.15
For a complete overview of all variables, see the questionnaire in
Data S1.
2.3 | Quality of life, treatment satisfaction, and
adherence
To evaluate the HRQoL, the Dutch translation of the QOLHEQ
was used, range 0-89. This disease-specific questionnaire con-
sists of 30 questions covering four subdomains: “symptoms”
(7 questions), “emotions” (8 questions), “functioning” (8 ques-
tions), and “treatment and prevention” (7 questions). Response
categories are never, rarely, sometimes, often, and always.7,8 For
the recently validated Dutch language version, these are scored
as 0, 1, 1, 2, and 3, respectively. The severity band for the
QOLHEQ overall score for Dutch patients is as follows: not at all,
0-13; slightly, 14-28; moderately, 29-44; strongly, 45-64; and
very strongly, ≥65.16
Satisfaction was assessed with the Dutch version of the Treat-
ment Satisfaction Questionnaire for Medication, version II (TSQM-II),
range 0-100.9 The TSQM-II is an 11-item validated questionnaire
comprising three domains: “effectiveness” (2 questions), “side effects”
(4 questions), and “convenience” (3 questions). Moreover, “global sat-
isfaction” (2 questions) was measured. Response categories are as fol-
lows: 1, extremely dissatisfied; 2, very dissatisfied; 3, dissatisfied;
4, somewhat satisfied; 5, satisfied; 6, very satisfied; and 7, extremely
satisfied. The score per domain can be calculated with an algorithm
ranging from 0 to 100, where higher scores equate to better
outcomes.
To evaluate treatment adherence four dichotomous questions
(yes [1]/no [0]), the 4-item Morisky Medication Adherence Scale was
used, range 0-4. A sum score of 0 represents a high patient adher-
ence, a score of 1 or 2 represents a medium adherence, and a score of
3 or 4 represents a low adherence.10
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2.4 | Statistical analyses
Data analyses were performed using IBM SPSS Statistics version 23.0
for Windows (SPSS/IBM, New York, New York). Descriptive statistics
were presented as mean together with median and range for interval-
scaled variables, and as relative frequency together with absolute
numbers for categorical variables. The four QOLHEQ and TSQM sub-
domains were analyzed separately for the group of patients with non-
systemic therapy and for the group with systemic therapy. After
controlling for normal distribution, the independent sample t test was
used to analyze the differences in treatment satisfaction and HRQoL
between both treatment groups. Fisher's exact test was used to test
difference in nominal variables between the nonsystemic and sys-
temic groups. Univariate regression analysis included as independent
variables age, gender, level of education (high vs middle/low), duration
of hand eczema (years), the current treatment (nonsystemic vs sys-
temic treatment), hand eczema severity, treatment adherence, and
“global satisfaction,” which were suitable for inclusion (P < .2) into the
multivariate regression model. Afterwards, multivariate linear regres-
sion was used including clinical characteristics associated with treat-
ment satisfaction. P-values less than .05 were considered statistically
significant in all analyses. Standardized β-coefficients were presented,
with strong correlation defined as β > 0.7, moderate correlation as
0.7 > β > 0.4, and weak correlation as 0.4 > β > 0.2.17 The interpret-
ability of the Dutch and International QOLHEQ (subdomain and over-
all) scores was published by Oosterhaven et al.8,16 See Data S3 for the
Dutch (Table S3.3) and International (Table S3.4) single score bands.
In this publication Dutch scores were presented; the International
scores can be found in Data S3.
3 | RESULTS
In total, 168 (56.0% female) participants were included in this study.
Sociodemographic and clinical characteristics are outlined in Table 1.
The mean duration (median [range]) of a diagnosis of hand eczema
TABLE 1 Patient characteristics





Number of patients, n (%) 168 (100) 74 (44.0) 94 (56.0) 112 (100) 56 (100)
Age (years), mean (SD) 43.1 (15.7) 44.4 (14.4) 42.0 (16.6) 67 (59.8) 27 (48.2)
High education, n (%) 35 (20.8) 15 (20.3) 20 (21.3) 40.0 (15.6)* 49.3 (14.1)*
High-risk occupation, n (%) 63 (37.5) 30 (40.5) 33 (35.1) 27 (24.1)* 8 (14.3)*
Duration of hand eczema (years), mean (SD) 9.2 (11.3) 10.1 (11.8) 8.5 (10.9) 48 (42.9) 17 (30.4)
Elevated total IgE level (>115 kU/L), n (%) 41 (37.6)d 21 (41.2)e 20 (34.5)f 7.5 (9.9)* 12.5 (13.3)*
Elevated serum-specific IgE inhaled allergens,
n (%)
52 (50.0)g 30 (60.0)h 22 (40.7)i 27 (39.7)j 14 (34.1)k
Etiological diagnosisc, n (%)
Atopic hand eczema 91 (54.2) 38 (51.4) 53 (56.4) 56 (50.0) 35 (62.5)
Irritant contact dermatitis 81 (48.2) 36 (48.6) 45 (47.9) 57 (50.9) 24 (42.9)
Allergic contact dermatitis 61 (39.6)d 26 (35.1)m 35 (37.2)n 42 (42.0)o 19 (35.2)p
Protein contact dermatitis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Etiologically unclassifiable hand eczema 20 (11.9)q 8 (10.8)r 12 (12.8) 16 (14.3)s 4 (7.1)
Current treatment, n (%)
Only topical treatmenta 111 (66.1) 45 (60.8) 66 (70.2) 111 (99.1) –
Systemic treatment 56 (33.3) 29 (39.2) 27 (28.7) – 56 (100)
Ciclosporin 25 (14.9) 11 (14.9) 14 (14.9) – 25 (44.6)
Alitretinoin 12 (7.1) 7 (9.5) 5 (5.3) – 12 (21.4)
Methotrexate 7 (4.2) 3 (4.1) 4 (4.3) – 7 (12.5)
Dupilumab 7 (4.2) 4 (5.4) 3 (3.2) – 7 (12.5)
Azathioprine 4 (2.4) 3 (4.1) 1 (1.1) – 4 (7.1)
Tacrolimus 1 (0.6) 1 (1.4) 0 (0) – 1 (1.8)
UV therapy 1 (0.6) 0 (0) 1 (1.1) 1 (0.9) –
Previous treatment, n (%)
Prior systemic treatmentb 65 (38.7) 25 (33.8) 40 (42.5) 24 (21.4)* 41 (73.2)*
One prior systemic treatment 30 (17.9) 9 (12.2) 21 (22.3) 14 (12.5)* 16 (28.6)*
(Continues)
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was 9.2 (11.3 [0.3-65]) years. The severity grades were pooled for the
total group (n = 168) because of the small numbers, clear (n = 6) and
almost clear (n = 74); severe (n = 31) and very severe (n = 9; Table 1).
Female patients had more often clear/almost clear hand eczema com-
pared with male patients, although this was only borderline signifi-
cant (P = .06).
Patch tests were performed in most patients (91.9%, n = 154).
Of the patch-tested patients 69.5% (n = 107) had at least one posi-
tive patch test reaction to an allergen from the European baseline
series. Most patients were patch tested with additional series;
79.2% (n = 122) had at least one positive reaction to allergens from
all series tested. Polysensitization was found in 24.0% (n = 37). Of
all patients, 37.5% (n = 63) had a high-risk occupation for develop-
ing hand eczema. See Data S2 for the list of these occupations.
The median (range) treatment duration for nonsystemic and sys-
temic treatments was 0.5 (0.3-32) years and 0.8 (0.3-7) years,
respectively.
3.1 | Health-related quality of life
The overall QOLHEQ scores indicated no impairment of HRQoL in
15.0% of patients (n = 25), slight impairment in 29.8% (n = 50), moder-
ate impairment in 38.1% (n = 64), strong impairment in 12.5%
(n = 21), and a very strong impairment in 4.2% (n = 7; Table 2). The
mean overall QOLHEQ scores and the mean QOLHEQ subdomain
scores are presented for the total group in Table 3, stratified by sex
and type of treatment (systemic vs nonsystemic). The mean overall
QOLHEQ score was 31.2, representing a moderately impaired
HRQoL. The most affected subdomain was “symptoms”; the mean
score was 9.1, representing a moderately impaired HRQoL. The other
mean QOLHEQ subdomains scores represented slightly impaired
HRQoL.
Differences in HRQoL impairment were evaluated for sex
and treatment groups. The overall QOLHEQ score and subdomain
“functioning” showed moderate impairment in females and slight
TABLE 1 (Continued)





More than one prior systemic treatment 35 (20.8) 16 (21.6) 19 (20.2) 10 (8.9)* 25 (44.6)*
Oral corticosteroids (<2 weeks) 60 (35.5) 29 (39.2) 31 (33.0) 32 (28.6)* 28 (50.0)*
UV therapy 58 (34.3) 23 (31.1) 35 (37.2) 44 (39.3) 14 (25.0)
Previous hospitalization 8 (4.8) 3 (4.1) 5 (5.3) 1 (0.9)* 4 (7.1)*
Disease severity, n (%)
Clear 6 (3.6) 2 (2.7) 4 (4.3) 3 (2.7) 3 (5.4)
Almost clear 74 (44.0) 26 (35.1) 48 (51.1) 45 (40.2) 29 (51.8)
Moderate 48 (28.6) 26 (35.1) 22 (23.4) 35 (31.3) 13 (23.2)
Severe 31 (18.5) 14 (18.9) 17 (18.1) 22 (19.6) 9 (16.1)
Very severe 9 (5.4) 6 (8.1) 3 (3.2) 7 (6.3) 2 (3.6)
aNonsystemic treatments included UV therapy, topical corticosteroids always combined with neutral emollients, occasionally with concomitant use of
calcineurin inhibitors or tar preparations.
bSystemic treatment included alitretinoin, acitretin, azathioprine, ciclosporin, dupilumab, methotrexate, mycophenolic acid/mycophenolate mofetil, oral
corticosteroids (>2 weeks), and tacrolimus.
cPatients can have one or more etiological hand eczema diagnoses.
d59 patients were not tested.
e23 patients were not tested.
f36 patients were not tested.
g64 patients were not tested.
h24 patients were not tested.
i40 patients were not tested.
j43 patients were not tested.
k33 patients were not tested.
l14 patients were not patch tested, necessary for allergic contact dermatitis classification.
mNine patients were not patch tested, necessary for allergic contact dermatitis classification.
nFive patients were not patch tested, necessary for allergic contact dermatitis classification.
o12 patients were not patch tested, necessary for allergic contact dermatitis classification.
pTwo patients were not patch tested, necessary for allergic contact dermatitis classification.
qThree patients were not patch tested, necessary for allergic contact dermatitis classification.
rThree patients were not patch tested, necessary for allergic contact dermatitis classification.
sThree patients were not patch tested, necessary for allergic contact dermatitis classification.
*P < .05, nonsystemic vs systemic treatment.
Abbreviations: IgE, immunoglobulin E; SD, standard deviation.
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impairment in males. The HRQoL impairment because of “symptoms”
was significantly lower in the group with systemic treatment com-
pared with the group with topical treatment. However, the mean
scores in both treatment groups represented moderately impaired
HRQoL.
The QOLHEQ overall scores were significantly different between
each of the severity groups (P < .001). In the pooled group of patients
with severe/very severe hand eczema (mean QOLHEQ overall score
41.1) and the group with moderate hand eczema (mean QOLHEQ
overall score 33.3) a moderate impairment of HRQoL was found.
The pooled group with clear/almost clear hand eczema (mean
QOLHEQ overall score 25.3) showed a slight impairment
(Table S3.1,S3.2).
3.2 | Treatment satisfaction
TSQM subdomain scores are presented in Table 3. Patients were most
satisfied about the TSQM subdomain “side effects” and least satisfied
about “effectiveness.” Patients receiving systemic treatment had sig-
nificantly higher TSQM treatment satisfaction scores for “effective-
ness” and “global satisfaction” compared with patients receiving
TABLE 2 Health-related quality of life impairment assessed with the Quality of Life in Hand Eczema Questionnaire (QOLHEQ) in patients
with vesicular hand eczema: interpretation of the overall QOLHEQ score and the QOLHEQ subdomain scores
Health-related quality of life impairmenta (n = 167)
Not at all (n, %) Slightly (n, %) Moderately (n, %) Strongly (n, %) Very strongly (n, %)
QOLHEQ overall score 25 (15.0) 50 (29.9) 64 (38.3) 21 (12.6) 7 (4.2)
Symptoms 2 (1.2) 60 (35.9) 48 (28.7) 45 (26.9) 12 (7.2)
Emotions 67 (40.1) 59 (35.3) 30 (18.0) 4 (2.4) 7 (4.2)
Functioning 17 (10.2) 77 (46.1) 34 (20.4) 26 (15.6) 13 (7.8)
Treatment and prevention 60 (35.9) 48 (28.7) 39 (23.4) 8 (4.8) 12 (7.2)
aOne patient missing.
TABLE 3 Means for health-related quality of life impairment (QOLHEQ), treatment satisfaction (TSQM), and treatment adherence (MMAS)




treatmenta (n = 112)
Systemic
treatmentb (n = 56)Male (n = 74) Female (n = 94) All (n = 168)
HRQoL impairment (QOLHEQ Dutch subscales), mean (SD)c
Overall score (0-89) 28.3 (14.4)** 33.6 (17.8)** 31.2 (16.5) 32.5 (16.0) 28.9 (17.4)
Symptoms (0-21) 8.4 (3.7)* 9.6 (4.4)* 9.1 (4.2) 9.8 (3.8)* 7.6 (4.5)*
Emotions (0-24) 6.9 (4.7) 7.8 (5.1) 7.4 (4.9) 7.7 (5.0) 6.9 (4.9)
Functioning (0-24) 6.5 (4.3)** 8.2 (5.6)** 7.4 (5.1) 7.6 (5.0) 7.1 (5.3)
Treatment and prevention (0-20) 7.3 (4.0)* 8.8 (4.7)* 8.1 (4.5) 8.3 (4.3) 7.8 (4.7)
Treatment satisfaction (TSQM subscale), mean (SD)
Effectiveness (0-100) 57.2 (17.7) 60.0 (19.0) 58.7 (18.4) 55.9 (17.9)* 64.4 (18.4)*
Side effects (0-100) 87.0 (21.1) 88.9 (19.1) 88.1 (19.9) 89.3 (20.2) 85.7 (19.4)
Convenience (0-100) 64.3 (17.1) 66.7 (12.5) 65.6 (14.7) 64.4 (13.0) 68.1 (17.5)
Global satisfaction (0-100) 61.0 (18.0) 64.2 (16.2) 62.7 (17.1) 60.8 (14.7)* 66.8 (20.6)*
Treatment adherence (MMAS-4), n (%)
High 18 (24.3)* 40 (42.6)* 58 (34.5) 31 (27.7)* 27 (48.2)*
Medium 41 (55.4) 43 (45.7) 84 (50.0) 58 (51.8) 26 (46.4)
Low 15 (20.3) 11 (11.7) 26 (15.5) 23 (20.5) 3 (5.4)
Abbreviations: HRQoL, health-related quality of life; MMAS-4, 4-item Morisky Medication Adherence Scale; QOLHEQ, Quality of Life in Hand Eczema
Questionnaire; SD, standard deviation; TSQM, Treatment Satisfaction Questionnaire for Medication.
aNonsystemic treatments included UV therapy, topical corticosteroids always combined with neutral emollients, occasionally with concomitant use of
calcineurin inhibitors or tar preparations.
bSystemic treatment included alitretinoin, azathioprine, ciclosporin, dupilumab, methotrexate, and tacrolimus.
cOne patient missing.
*P < .05 (male vs female and systemic vs nonsystemic treatment), **P < .05 and different severity band.
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nonsystemic treatment (Table 3). “Global satisfaction” scores for non-
systemic vs different individual systemic treatments are presented in
Figure 1. Significantly higher “global satisfaction” scores were found
for ciclosporin, alitretinoin, and dupilumab compared with non-
systemic treatment. Figure 2 shows the mean TSQM subdomain
scores in different severity groups. Patients with severe/very severe
hand eczema had significantly lower subdomain satisfaction scores in
“effectiveness” (TSQM score: 47.3, standard deviation [SD]: 14.9)
compared with patients with moderate (TSQM score: 55.4, SD: 15.0) or
clear/almost clear hand eczema (TSQM score: 66.4, SD: 18.4), P < .001.
Furthermore, TSQM subdomain scores of “global satisfaction” were sig-
nificantly lower for severe/very severe hand eczema (TSQM score:
F IGURE 1 Treatment satisfaction
scores (TSQM, range 0-100) for
nonsystemic treatment vs different
individual systemic treatments. A higher
score of the TSQM subdomain “global
satisfaction” indicates higher levels of
treatment satisfaction. *P < .05. Other
treatments are azathioprine, tacrolimus,
and UV therapy. TSQM, Treatment
Satisfaction Questionnaire for Medication
F IGURE 2 Treatment satisfaction
domain scores (TSQM, range 0-100) in
different hand eczema severity groups.
Higher scores in the TSQM domains
(bars) indicate higher levels of treatment
satisfaction. Error bars represent
standard deviation. *P < .05 between
groups. TSQM, Treatment Satisfaction
Questionnaire for Medication
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50.4, SD: 14.6) compared with patients with moderate (TSQM
score: 61.1, SD: 15.8) or clear/almost clear hand eczema (TSQM score:
69.9, SD: 15.2), P < .001. No significant association between age, hand
eczema duration, previous history of systemic treatment, and treatment
satisfaction was found.
3.3 | Adherence
About 50% of the patients had a medium treatment adherence. In the
group of patients with high treatment adherence there were signifi-
cantly more females than males and significantly more patients using
systemic therapy compared with nonsystemic therapy (Table 3). The
QOLHEQ and TSQM subdomains scores for different adherence
groups are presented in Table 4. A high adherence was significantly
associated with a lower QOLHEQ overall score and the QOLHEQ
subdomain “emotions.” Moreover, high adherence was associated
with higher TSQM “global satisfaction” scores and a higher satisfac-
tion about “effectiveness.”
3.4 | Regression analysis
In the univariate analysis (see Data S4), taking the QOLHEQ domain
score as the dependent variable, age, duration of hand eczema,
education, and adherence were not associated with HRQoL. The
multivariate regression model (Table 5) showed that female sex,
more severe hand eczema, and lower treatment satisfaction were
associated with more impairment of HRQoL (overall QOLHEQ
score). This model explained 37% of the variance of the total
HRQoL score (R2). Severity was strongly associated with the
QOLHEQ subdomain “symptoms.” For the association of “global
satisfaction,” the standardized beta was similar for all QOLHEQ
subdomains. Female sex was not associated with the QOLHEQ sub-
domain “emotions.”
TABLE 4 Means of health-related quality of life (HRQoL)









HRQoL impairment (QOLHEQ Dutch subdomains), mean (SD)a
Symptoms (0-21) 10.0 (3.2) 9.5 (3.7) 8.0 (4.9)
Emotions (0-24) 7.5 (4.6)* 8.4 (4.8)* 5.9 (4.9)*
Functioning (0-24) 7.4 (4.9) 8.2 (4.9) 6.2 (5.4)
Treatment and
prevention (0-20)
8.4 (4.1) 8.8 (4.1) 7.1 (5.0)





















Abbreviations: MMAS-4, 4-item Morisky Medication Adherence Scale;
QOLHEQ, Quality of Life in Hand Eczema Questionnaire; SD, standard
deviation; TSQM, Treatment Satisfaction Questionnaire for Medication.
aOne patient missing.
*P < .05.
TABLE 5 Multivariate linear regression analysis assessing factors that would affect the health-related quality of life subdomain scores as the
dependent variable
Variable
Symptoms subdomain Emotions subdomain Functioning subdomain
Treatment and
prevention subdomain QOLHEQ overall score
R2 = 0.41 R2 = 0.26 R2 = 0.33 R2 = 0.25 R2 = 0.37
Standardized β P-value Standardized β P-value Standardized β P-value Standardized β P-value Standardized β P-value
Sex (female) 0.23 <.001 – – 0.23 .00 0.23 <.001 0.25 <.001




−0.10 .11 – – – – – – 0.05 .51
Severity 0.33 <.001 0.16 .04 0.19 .01 0.14 .08 0.22 <.001





−0.36 <.001 −0.41 <.001 −0.43 <.001 −0.40 <.001 −0.44 <.001
Note: Numbers in bold represent P < .05 and standardized β coefficients >0.2.
Note: Variables with a indent (−) had a P value > .2 in the univariate regression analysis and were not suitable for inclusion in the concerning subdomain.
Abbreviations: QOLHEQ, Quality of Life in Hand Eczema Questionnaire; TSQM, Treatment Satisfaction Questionnaire for Medication.
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4 | DISCUSSION
Overall, vesicular hand eczema patients showed a moderately
impaired HRQoL, with the highest impairment noted in the QOLHEQ
subdomain “symptoms.” We demonstrated that more severe hand
eczema was associated with more impairment in HRQoL. The associa-
tion between severity and HRQoL is in line with previous studies that
used the Dermatology Life Quality Index to assess HRQoL and
included all types of hand eczema.6,18 Female sex was associated with
more impairment in HRQoL. Female sex is a well-known demographic
factor affecting HRQoL. Other studies showed that female patients
experienced more HRQoL impairment compared with male patients,
or had similar impairment with less severe hand eczema.2,6,7 In the
current study “functioning” was particularly affected in females.
Female patients probably had more distress related to limitations in
work, leisure time, or domestic activities. Previous studies showed a
considerable psychosocial burden of hand eczema and underline that
anxiety and depression are more common in female patients.2,19 In
this study we did not find an association between female sex and
impairment of HRQoL in the QOLHEQ subdomain “emotions.” The
regression analyses showed that lower “global satisfaction” was asso-
ciated with more impairment of HRQoL; the standardized beta was
−0.44, which indicates a moderate correlation. In previous studies in
patients with gout and hypertension a correlation was also found
between these outcomes.20,21
For the total group we have shown that patients were least satis-
fied with “effectiveness” of treatment. In patients with severe and
very severe hand eczema significantly lower satisfaction scores were
found for the TSQM subdomains “effectiveness” and “global satisfac-
tion” compared with the other severity groups. Satisfaction about
“side effects” and “convenience” were similar in the different severity
groups. This implies that effectiveness of treatment is the major factor
affecting “global satisfaction,” which is supported by previous studies
on, for example, patients with psoriasis and lichen sclerosis. These
studies found that patients reported treatment effectiveness as the
most important factor for overall treatment satisfaction.2,22,23 The
group using systemic treatment presented significantly higher satis-
faction scores with regard to the “effectiveness,” compared with the
group without systemic treatment. The “global satisfaction” was sig-
nificantly higher for alitretinoin, ciclosporin, and dupilumab compared
with nonsystemic treatments. In patients with psoriasis data also
showed lower “global satisfaction” scores for patients receiving non-
systemic treatment.24,25 The use of biologicals for psoriasis resulted in
substantially higher global patient satisfaction scores.24,26 Recent
observational studies showed promising results regarding the effec-
tiveness of dupilumab in patients with hand eczema and might offer
future perspectives for patients with difficult-to-treat vesicular hand
eczema.27,28
Treatment adherence was significantly lower in patients
receiving nonsystemic treatment compared with systemic treat-
ment. The perception of the relative ineffectiveness and inconve-
nience of topical treatment and sometimes corticophobia are well
known in dermatology. This may hinder adherence and treatment
effectiveness.29-31 Concerning adherence and QOLHEQ sub-
domains there was a significant association for the QOLHEQ over-
all and “emotional” subdomain scores, indicating that high
adherence comes in line with less (emotional) HRQoL impairment
(Table 4). However, a longitudinal study is needed to verify if less
emotional impairment leads to higher adherence or if adherence
leads to less emotional problems. A higher medication adherence
was also significantly associated with a higher “global satisfaction,”
while this effect was not seen in the TSQM subdomains “side
effects” and “effectiveness.”
Some clinical and etiological characteristics need to be
highlighted. Of note, half of the patients had ICD during treatment
phase (>3 months) and even in the group treated with systemic ther-
apy 40% had an ICD. In our department advanced nurse practitioners
provide one-to-one patient education for every patient with hand
eczema. These are offered personalized glove advice to protect hands
from irritant and allergic factors and improve topical treatment com-
pliance. From the high proportion of ICD it can be deduced that
despite all efforts it seems impossible for a large proportion of
patients to avoid exposure to irritants.
Moreover, we found a high proportion of patients with allergic
contact dermatitis (40%), compared with other studies.32,33 A possible
explanation is the fact that our center is a tertiary reference center for
hand eczema. Finally, atopic dermatitis is a well-known risk factor for
more severe and chronic hand eczema.34 The number of patients with
an atopic hand eczema in this study was in line with previous studies
(21.5%-57.5%).32,33
A limitation of our study is the monocentric design in a tertiary
referral center. Presumably this patient cohort included more patients
with a difficult-to-treat hand eczema in all groups. Nonsystemic treat-
ment was compared with systemic treatment in terms of HRQoL and
treatment satisfaction. Patients on systemic treatment are in general
more difficult to treat and an effective treatment will influence their
HRQoL and treatment satisfaction more strongly. Another limitation
of our study is the smaller number of participants treated with sys-
temic medication compared with nonsystemic medication and the
small subgroups with individual systemic treatments. The majority of
the patients reported relatively high satisfaction scores for systemic
treatment. However, patients with higher levels of satisfaction were
more likely to continue with treatment and therefore maybe overrep-
resented. Patients who discontinued treatment because of side
effects or inefficacy within 3 months were not included because of
our inclusion criteria of treatment longer than 3 months. This is proba-
bly one of the reasons for the favorable results for alitretinoin, which
was previously demonstrated to be less successful in vesicular hand
eczema.35 If alitretinoin is effective, patients will continue treatment
after 3 months.
In conclusion, our results indicate that disease severity affects
both HRQoL and treatment satisfaction in patients with vesicular
hand eczema. Patients only using topical treatment are less satisfied
with their treatment and their treatment adherence is lower. Systemic
treatment of severe hand eczema could improve the severity and as a
result also HRQoL, treatment satisfaction, and medication adherence.
8 POLITIEK ET AL.
New systemic treatment options for patients with severe hand
eczema, for example, biologicals or small molecules, could possibly
contribute to this.
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